Be part of the knowledge.™

Clinical Pharmacology

733

LikeLikedUnlike

121-135 of 235

Potentially Huge Savings When Patients Adhere to their Prescriptions
Clinician's Roundtable
Potentially Huge Savings When Patients Adhere to their Prescriptions
- Steve Miller, MD
  Peer
- Bruce Japsen
  Peer
Repurposing Drugs: Challenges and Triumphs from an Emerging Field
Proto: Dispatches from the Frontiers of Medicine
Repurposing Drugs: Challenges and Triumphs from an Emerging Field
- Frances Toneguzzo, PhD
  Peer
- Bruce Bloom, DDS, JD
  Peer
- David Borsook, MD, PhD
  Peer
The FDA's Safe Use Initiative
Focus on Pharmacy
The FDA's Safe Use Initiative
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
The Benefits of TZDs for Early Type 2 Diabetes
Diabetes Discourse
The Benefits of TZDs for Early Type 2 Diabetes
- John (Jack) L. Leahy, MD
  Peer
- Steven Edelman, MD
  Peer
Oral Agents for Diabetes: What to Choose and When
Diabetes Discourse
Oral Agents for Diabetes: What to Choose and When
- Andrew Ahmann, MD
  Peer
- Steven Edelman, MD
  Peer
The Battle Continues Against Pharmacological Cheating in Sports
Focus on Sports Medicine
The Battle Continues Against Pharmacological Cheating in Sports
- Gary Wadler, MD
  Peer
- Bruce Japsen
  Peer
advertisement
Rewriting the DSM
Focus on Neurology and Psychiatry
Rewriting the DSM
- Darrel Regier, MD
  Peer
- Bruce Japsen
  Peer
Multiple Choice: Customizing Insulin Therapy
Diabetes Discourse
Multiple Choice: Customizing Insulin Therapy
- Matthew Riddle, MD
  Peer
- Steven Edelman, MD
  Peer
As Prescribed: Meeting the Challenges of Medication Adherence
Heart Matters
As Prescribed: Meeting the Challenges of Medication Adherence
- Janet Wright, MD
  Peer
- Michael Ho, MD, PhD
  Peer
In-Office Drug Testing for Retinal Conditions
Revealing Retina
In-Office Drug Testing for Retinal Conditions
- Roy Levit, MD
  Peer
- Allen Verne, MD
  Peer
Clinical Care Implications of ALLHAT
Diabetes Discourse
Clinical Care Implications of ALLHAT
- Debra Simmons, MD
  Peer
- Steven Edelman, MD
  Peer
The Potential of Immunotherapy in Type 1 Diabetes
Diabetes Discourse
The Potential of Immunotherapy in Type 1 Diabetes
- Matthias von Herrath, MD
  Peer
- Steven Edelman, MD
  Peer
advertisement
Emerging Insulin Pump Technology
Diabetes Discourse
Emerging Insulin Pump Technology
- Nancy Bohannon, MD
  Peer
- Steven Edelman, MD
  Peer
Interventions Targeting Impaired Glucose Tolerance
Diabetes Discourse
Interventions Targeting Impaired Glucose Tolerance
- Robert Henry, MD
  Peer
- Steven Edelman, MD
  Peer
The ARBITER 6-HALTS Trial: Clinical Implications
Heart Matters
The ARBITER 6-HALTS Trial: Clinical Implications
- Christopher Cannon, MD
  Peer
- Jack Lewin, MD
  Peer

Program Chapters

Segment Chapters

Playlist:

Recommended